(Q34934444)

5 August 2017

1 reference

title

Is there a formula for an effective CMV vaccine? (English)

1 reference

5 August 2017

Stanley A Plotkin

1 reference

5 August 2017

publication date

1 August 2002

1 reference

Journal of Clinical Virology

5 August 2017

published in

1 reference

5 August 2017

volume

25 Suppl 2

1 reference

5 August 2017

page(s)

S13-21

1 reference

Immunity induced by primary human cytomegalovirus infection protects against secondary infection among women of childbearing age.

5 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2802%2900093-8

7 January 2021

Safety and immunogenicity of the Towne strain cytomegalovirus vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2802%2900093-8

7 January 2021

Report on a long-term study of maternal and congenital cytomegalovirus infection in Sweden. Review of prospective studies available in the literature

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2802%2900093-8

7 January 2021

Cytomegalovirus: the troll of transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2802%2900093-8

7 January 2021

A canarypox vector-expressing cytomegalovirus (CMV) phosphoprotein 65 induces long-lasting cytotoxic T cell responses in human CMV-seronegative subjects

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2802%2900093-8

7 January 2021

Antiviral antibody responses and intrauterine transmission after primary maternal cytomegalovirus infection

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2802%2900093-8

7 January 2021

Symptomatic congenital cytomegalovirus infection in infants born to mothers with preexisting immunity to cytomegalovirus

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2802%2900093-8

7 January 2021

Preconception immunization with a cytomegalovirus (CMV) glycoprotein vaccine improves pregnancy outcome in a guinea pig model of congenital CMV infection

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2802%2900093-8

7 January 2021

Cytomegalovirus immune globulin and seronegative blood products to prevent primary cytomegalovirus infection after marrow transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2802%2900093-8

7 January 2021

Effect of passive antibody on congenital cytomegalovirus infection in guinea pigs

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2802%2900093-8

7 January 2021

Neonatal screening for congenital cytomegalovirus infections

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2802%2900093-8

7 January 2021

Vaccination of seropositive subjects with CHIRON CMV gB subunit vaccine combined with MF59 adjuvant for production of CMV immune globulin

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2802%2900093-8

7 January 2021

Induction of human cytomegalovirus (HCMV)-glycoprotein B (gB)-specific neutralizing antibody and phosphoprotein 65 (pp65)-specific cytotoxic T lymphocyte responses by naked DNA immunization

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2802%2900093-8

7 January 2021

Protection against murine cytomegalovirus infection by passive transfer of neutralizing and non-neutralizing monoclonal antibodies

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2802%2900093-8

7 January 2021

The outcome of congenital cytomegalovirus infection in relation to maternal antibody status

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2802%2900093-8

7 January 2021

Effects of antigen dose and immunization regimens on antibody responses to a cytomegalovirus glycoprotein B subunit vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2802%2900093-8

7 January 2021

Development of a cytomegalovirus vaccine: lessons from recent clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2802%2900093-8

7 January 2021

Delayed type hypersensitivity to human cytomegalovirus

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2802%2900093-8

7 January 2021

Cytotoxic T lymphocyte (CTL) responses to human cytomegalovirus pp65, IE1-Exon4, gB, pp150, and pp28 in healthy individuals: reevaluation of prevalence of IE1-specific CTLs

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2802%2900093-8

7 January 2021

Screening and diagnosis of congenital cytomegalovirus infection: a 5-y study

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2802%2900093-8

7 January 2021

Reduced Congenital Cytomegalovirus (CMV) Infection after Maternal Immunization with a Guinea Pig CMV Glycoprotein before Gestational Primary CMV Infection in the Guinea Pig Model

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2802%2900093-8

7 January 2021

T cell proliferative responses to five human cytomegalovirus proteins in healthy seropositive individuals: implications for vaccine development

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2802%2900093-8

7 January 2021

Efficient lytic infection of human arterial endothelial cells by human cytomegalovirus strains

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2802%2900093-8

7 January 2021

Defined large-scale alterations of the human cytomegalovirus genome constructed by cotransfection of overlapping cosmids

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2802%2900093-8

7 January 2021

Delayed acquisition of high-avidity anti-cytomegalovirus antibody is correlated with prolonged antigenemia in solid organ transplant recipients

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2802%2900093-8

7 January 2021

Human cytomegalovirus neutralizing antibody-resistant phenotype is associated with reduced expression of glycoprotein H

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2802%2900093-8

7 January 2021

Cytomegalovirus antibody avidity in allogeneic bone marrow recipients: evidence for primary or secondary humoral responses depending on donor immune status

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2802%2900093-8

7 January 2021

Suppression of murine cytomegalovirus (MCMV) replication with a DNA vaccine encoding MCMV M84 (a homolog of human cytomegalovirus pp65)

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2802%2900093-8

7 January 2021

Epidemiology of congenital cytomegalovirus infection: maternal risk factors and molecular analysis of cytomegalovirus strains

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2802%2900093-8

7 January 2021

A subunit cytomegalovirus vaccine based on recombinant envelope glycoprotein B and a new adjuvant

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2802%2900093-8

7 January 2021

CYTOMEGALOVIRUS INFECTION IN PREGNANCY: PRELIMINARY FINDINGS FROM A PROSPECTIVE STUDY

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2802%2900093-8

7 January 2021

Dense bodies of human cytomegalovirus induce both humoral and cellular immune responses in the absence of viral gene expression

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2802%2900093-8

7 January 2021

Effect of Towne live virus vaccine on cytomegalovirus disease after renal transplant. A controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2802%2900093-8

7 January 2021

Vaccination against cytomegalovirus, the changeling demon

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2802%2900093-8

7 January 2021

Cytotoxic t cells in cytomegalovirus infection: HLA-restricted T-lymphocyte and non-T-lymphocyte cytotoxic responses correlate with recovery from cytomegalovirus infection in bone-marrow-transplant recipients

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2802%2900093-8

7 January 2021

The immunogenicity of human and murine cytomegaloviruses

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2802%2900093-8

7 January 2021

Cytomegalovirus (CMV)-specific T cell immunity after renal transplantation mediates protection from CMV disease by limiting the systemic virus load

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2802%2900093-8

7 January 2021

Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2802%2900093-8

7 January 2021

The humoral immune response against human cytomegalovirus is characterized by a delayed synthesis of glycoprotein-specific antibodies

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2802%2900093-8

7 January 2021

Use of cytomegalovirus immunoglobulin in multiply transfused premature neonates

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2802%2900093-8

7 January 2021

Congenital cytomegalovirus infection: The relative importance of primary and recurrent maternal infection

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2802%2900093-8

7 January 2021

Preemptive CD8 T-cell immunotherapy of acute cytomegalovirus infection prevents lethal disease, limits the burden of latent viral genomes, and reduces the risk of virus recurrence

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2802%2900093-8

7 January 2021

Neuropathogenesis induced by rhesus cytomegalovirus in fetal rhesus monkeys (Macaca mulatta).

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2802%2900093-8

7 January 2021

Proliferative T cell responses to four human cytomegalovirus-specific proteins in healthy subjects and solid organ transplant recipients

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2802%2900093-8

7 January 2021

Prevention of transfusion-acquired cytomegalovirus infections in newborn infants

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2802%2900093-8

7 January 2021

10.1016/S1386-6532(02)00093-8

Identifiers

DOI

1 reference

5 August 2017

1 reference